Alzheimer’s Disease Studies

“A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers (Janssen)”

“A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E ε4 Non-Carriers (Janssen)”

“A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers (Wyeth)”

These three separate international trials are dedicated to the treatment of Alzheimer’s disease.  Specifically, these clinical trials investigate if multiple doses of intravenously administered Bapineuzumab is indicative of disease modification in subsets of patients with mild to moderate Alzheimer’s disease.  The goal is to explore if this investigational drug can help control the progression of Alzheimer’s disease. The studies are 18 months in duration and involve 7 MRIs and 6 infusions of the investigational drug or placebo.  It is important for patients and families affected by Alzheimer’s disease to consider participating in clinical studies investigators of new drug treatment to increase the chance of fighting this disease.  UAB site: Principal Investigator: F. Cleveland Kinney, M.D., Ph.D.; Sub-Investigator(s): Daniel Dahl, M.D.; Terri Steele, M.D.;Bates Redwine, M.D.

Study Coordinators: Hollis Reeves 205-975-0068 and  Roberta May (205) 934-2605.